In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., also had been resolved. Zepbound is approved to treat obesity and Mounjaro is approved for diabetes. They use the same active ingredient, tirzepatide.

Research shows bimagrumab may prevent muscle and bone loss associated with weight loss medications like Wegovy, offering hope for safer treatment options.